![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BIOGEN IDEC, INC. AND ALNYLAM PHARMACEUTICALS FORM ALLIANCE TO DISCOVER AND DEVELOP THERAPEUTICS FOR THE POTENTIAL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
BIOGEN IDEC, INC. AND ALNYLAM PHARMACEUTICALS FORM ALLIANCE TO DISCOVER AND DEVELOP THERAPEUTICS FOR THE POTENTIAL TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
Biogen Idec and Alnylam Pharmaceuticals, Inc. announced a collaboration to discover and develop RNAi therapeutics for the potential treatment of progressive multifocal leukoencephalopathy (PML). PML is caused by infection of the central nervous system with a virus called "JC virus" and can occur in certain immune-suppressed patients, including those receiving immunomodulatory therapies.
BioSpace (http://www.biospace.com/news_story.aspx?StoryID=30687&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct